Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting

Investor Contact:

International Media Contact:

U.S. Media Contact:

S.A. Noonan Communications

JW Communications

Rx Communications Group, LLC

Susan A. Noonan

Julia Wilson

Melody Carey

+1-212-966-3650

+44 (0)7818 430877

+ 1-917-322-2571

[email protected]

[email protected]

[email protected]